bit.bio

A Cambridge company that programs human stem cells into consistent, ready-to-use human cells for disease research and drug development.

About bit.bio

bit.bio is a Cambridge-based company that programs human cells. Its ioCells range includes heart, liver, muscle, nerve and support cells, made with its opti-ox technology, and it offers CRISPR screening and custom cell development. Researchers use these cells to study disease and test medicines.

In June 2026 its new chief executive described the goal as "setting a new standard in biology by delivering consistent, defined human cells at scale". The company aims to give researchers human-relevant models for disease research and drug development.

bit.bio is based in Cambridge, UK. Its June 2026 news confirms it is still trading, with Dr Emma Pepperell appointed chief executive after being its VP Commercial.

The company page links to diversity and inclusion, sustainability and careers pages and invites visitors to "Join our pioneering team", but we did not find values wording or staff numbers.

When we checked its job board it said there were no current openings. We found no graduate scheme, internship or apprenticeship details, so check bit.bio's careers page in future.

What they do

• {'desc': 'Ready-to-use human cell types for research.', 'title': 'ioCells'}
• {'desc': 'Genetic screening services using its cells.', 'title': 'CRISPR screening'}
• {'desc': 'Building new cell types for customers.', 'title': 'Custom cell development'}

Key facts

• Cambridge, UK
• CEO change announced 12 June 2026
• Core technology called opti-ox
• Job board showed no current openings (checked 20 Oct 2026)

Website: www.bit.bio